Human glioblastoma arises from subventricular zone cells with low-level driver mutations

JH Lee, JE Lee, JY Kahng, SH Kim, JS Park, SJ Yoon… - Nature, 2018 - nature.com
Glioblastoma (GBM) is a devastating and incurable brain tumour, with a median overall
survival of fifteen months,. Identifying the cell of origin that harbours mutations that drive …

Leptomeningeal spread in glioblastoma: diagnostic and therapeutic challenges

C Birzu, S Tran, F Bielle, M Touat, K Mokhtari… - The …, 2020 - academic.oup.com
Background Glioblastoma (GBM) is the most common and aggressive primary malignant
brain tumor. Leptomeningeal spread (LMS) is a severe complication of GBM, raising …

Recent advances in oncolytic virotherapy and immunotherapy for glioblastoma: a glimmer of hope in the search for an effective therapy?

AA Stepanenko, VP Chekhonin - Cancers, 2018 - mdpi.com
To date, no targeted drugs, antibodies or combinations of chemotherapeutics have been
demonstrated to be more efficient than temozolomide, or to increase efficacy of standard …

Progress toward long-term survivors of glioblastoma

JN Cantrell, MR Waddle, M Rotman, JL Peterson… - Mayo clinic …, 2019 - Elsevier
Objective To identify the frequency and characteristics of long-term survivors of
glioblastoma. Patients and Methods Using all cases of glioblastoma with histopathological …

Etomoxir, a carnitine palmitoyltransferase 1 inhibitor, combined with temozolomide reduces stemness and invasiveness in patient-derived glioblastoma tumorspheres

JK Shim, S Choi, SJ Yoon, RJ Choi, J Park… - Cancer Cell …, 2022 - Springer
Introduction The importance of fatty acid oxidation (FAO) in the bioenergetics of glioblastoma
(GBM) is being realized. Etomoxir (ETO), a carnitine palmitoyltransferase 1 (CPT1) inhibitor …

Survival benefit of lobectomy over gross-total resection without lobectomy in cases of glioblastoma in the noneloquent area: a retrospective study

TH Roh, SG Kang, JH Moon, KS Sung, HH Park… - Journal of …, 2019 - thejns.org
OBJECTIVE Following resection of glioblastoma (GBM), microscopic remnants of the GBM
tumor remaining in nearby tissue cause tumor recurrence more often than for other types of …

Classification of IDH wild-type glioblastoma tumorspheres into low-and high-invasion groups based on their transcriptional program

J Park, JK Shim, M Lee, D Kim, SJ Yoon… - British journal of …, 2023 - nature.com
Background Glioblastoma (GBM), one of the most lethal tumors, exhibits a highly infiltrative
phenotype. Here, we identified transcription factors (TFs) that collectively modulate invasion …

Effect of combined anti-PD-1 and temozolomide therapy in glioblastoma

J Park, CG Kim, JK Shim, JH Kim, H Lee, JE Lee… - …, 2019 - Taylor & Francis
ABSTRACT Background: Although programmed death-1 (PD-1) blockade is effective in
treating several types of cancer, the efficacy of this agent in glioblastoma (GBM) is largely …

Association between survival and levetiracetam use in glioblastoma patients treated with temozolomide chemoradiotherapy

TH Roh, JH Moon, HH Park, EH Kim, CK Hong… - Scientific reports, 2020 - nature.com
This study was conducted to assess whether levetiracetam (LEV) affects the survival of
patients with glioblastoma (GBM) treated with concurrent temozolomide (TMZ) …

Tumor treating fields and maintenance temozolomide for newly-diagnosed glioblastoma: a cost-effectiveness study

GF Guzauskas, EL Pollom, VW Stieber… - Journal of medical …, 2019 - Taylor & Francis
Purpose: The EF-14 trial demonstrated that adding tumor treating fields (TTFields) to
maintenance temozolomide (TMZ) significantly extends progression-free survival (PFS) and …